QQQ   271.64 (-3.90%)
AAPL   111.20 (-4.63%)
MSFT   202.68 (-4.96%)
FB   267.67 (-5.51%)
GOOGL   1,510.80 (-5.51%)
AMZN   3,162.78 (-3.76%)
TSLA   406.02 (-4.39%)
NVDA   505.08 (-5.75%)
BABA   307.94 (-2.90%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.00 (-3.77%)
AMD   76.40 (-3.14%)
T   26.50 (-1.56%)
F   7.70 (-2.78%)
ACB   3.83 (-4.25%)
GILD   58.72 (-2.15%)
NFLX   486.24 (-0.55%)
NIO   27.51 (-3.27%)
BA   148.14 (-4.57%)
DIS   118.47 (-3.93%)
QQQ   271.64 (-3.90%)
AAPL   111.20 (-4.63%)
MSFT   202.68 (-4.96%)
FB   267.67 (-5.51%)
GOOGL   1,510.80 (-5.51%)
AMZN   3,162.78 (-3.76%)
TSLA   406.02 (-4.39%)
NVDA   505.08 (-5.75%)
BABA   307.94 (-2.90%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.00 (-3.77%)
AMD   76.40 (-3.14%)
T   26.50 (-1.56%)
F   7.70 (-2.78%)
ACB   3.83 (-4.25%)
GILD   58.72 (-2.15%)
NFLX   486.24 (-0.55%)
NIO   27.51 (-3.27%)
BA   148.14 (-4.57%)
DIS   118.47 (-3.93%)
QQQ   271.64 (-3.90%)
AAPL   111.20 (-4.63%)
MSFT   202.68 (-4.96%)
FB   267.67 (-5.51%)
GOOGL   1,510.80 (-5.51%)
AMZN   3,162.78 (-3.76%)
TSLA   406.02 (-4.39%)
NVDA   505.08 (-5.75%)
BABA   307.94 (-2.90%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.00 (-3.77%)
AMD   76.40 (-3.14%)
T   26.50 (-1.56%)
F   7.70 (-2.78%)
ACB   3.83 (-4.25%)
GILD   58.72 (-2.15%)
NFLX   486.24 (-0.55%)
NIO   27.51 (-3.27%)
BA   148.14 (-4.57%)
DIS   118.47 (-3.93%)
QQQ   271.64 (-3.90%)
AAPL   111.20 (-4.63%)
MSFT   202.68 (-4.96%)
FB   267.67 (-5.51%)
GOOGL   1,510.80 (-5.51%)
AMZN   3,162.78 (-3.76%)
TSLA   406.02 (-4.39%)
NVDA   505.08 (-5.75%)
BABA   307.94 (-2.90%)
CGC   18.34 (-1.71%)
GE   7.42 (+4.51%)
MU   50.00 (-3.77%)
AMD   76.40 (-3.14%)
T   26.50 (-1.56%)
F   7.70 (-2.78%)
ACB   3.83 (-4.25%)
GILD   58.72 (-2.15%)
NFLX   486.24 (-0.55%)
NIO   27.51 (-3.27%)
BA   148.14 (-4.57%)
DIS   118.47 (-3.93%)
Log in
OTCMKTS:INNV

Innovus Pharmaceuticals Stock Forecast, Price & News

$1.23
+0.07 (+6.03 %)
(As of 02/14/2020)
Add
Compare
Today's Range
$1.11
Now: $1.23
$1.23
50-Day Range
$1.23
MA: $1.23
$1.23
52-Week Range
$0.75
Now: $1.23
$11.50
Volume13,200 shs
Average Volume16,010 shs
Market Capitalization$3.94 million
P/E RatioN/A
Dividend YieldN/A
Beta2.1
Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, ketones, krill oil, omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; UriVarx, a supplement for overactive bladder and urinary incontinence; PEVarx, a supplement for peak sexual performance; ProstaGorx, a supplement for prostate support; and FlutiCare, a nasal spray. In addition, its products include Apeaz for pain relief; AllerVarx for allergy relief; ArthriVarx for joint pain; Xyralid, a hemorrhoid cream; Can-C eye drop and eye care capsule; MZS, a melatonin formula to enhance sleep patterns; and Diabasens, a diabetic foot cream. The company's pipeline products comprise UriVarx for urinary tract infection; Xyralid suppositories for hemorrhoidal symptoms; GlucoGorx supplement, glucometer, lancing device, and GlucoGorx strip for blood sugar levels; Vesele and RecalMax nitric oxide strips. It markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
Read More
Innovus Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.16 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:INNV
Previous SymbolNASDAQ:INNV
CUSIPN/A
Phone858-964-5123
Employees27

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.99 million
Book Value$0.05 per share

Profitability

Net Income$-8,280,000.00

Miscellaneous

Market Cap$3.94 million
Next Earnings DateN/A
OptionableNot Optionable
$1.23
+0.07 (+6.03 %)
(As of 02/14/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive INNV News and Ratings via Email

Sign-up to receive the latest news and ratings for INNV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Innovus Pharmaceuticals (OTCMKTS:INNV) Frequently Asked Questions

How has Innovus Pharmaceuticals' stock been impacted by Coronavirus?

Innovus Pharmaceuticals' stock was trading at $1.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, INNV shares have increased by 0.0% and is now trading at $1.23.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Innovus Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Innovus Pharmaceuticals
.

How were Innovus Pharmaceuticals' earnings last quarter?

Innovus Pharmaceuticals, Inc. (OTCMKTS:INNV) issued its earnings results on Tuesday, August, 14th. The company reported ($0.01) earnings per share (EPS) for the quarter. The business had revenue of $7.31 million for the quarter. Innovus Pharmaceuticals had a negative return on equity of 1,611.96% and a negative net margin of 35.85%.
View Innovus Pharmaceuticals' earnings history
.

What price target have analysts set for INNV?

1 Wall Street analysts have issued 12 month target prices for Innovus Pharmaceuticals' shares. Their forecasts range from $5.00 to $5.00. On average, they expect Innovus Pharmaceuticals' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 306.5% from the stock's current price.
View analysts' price targets for Innovus Pharmaceuticals
.

Who are some of Innovus Pharmaceuticals' key competitors?

What other stocks do shareholders of Innovus Pharmaceuticals own?

Who are Innovus Pharmaceuticals' key executives?

Innovus Pharmaceuticals' management team includes the following people:
  • Dr. Bassam B. Damaj, Pres, CEO & Director (Age 51)
  • Mr. Ryan J. Selhorn CPA, VP & CFO (Age 37)
  • Mr. Randy J. Berholtz, Exec. VP of Corp. Devel., Gen. Counsel & Sec. (Age 58)
  • Mr. Christopher Stella, VP of Operations
  • Mr. Robert C. Verfurth, VP of Sales & Marketing

What is Innovus Pharmaceuticals' stock symbol?

Innovus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "INNV."

How do I buy shares of Innovus Pharmaceuticals?

Shares of INNV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Innovus Pharmaceuticals' stock price today?

One share of INNV stock can currently be purchased for approximately $1.23.

How big of a company is Innovus Pharmaceuticals?

Innovus Pharmaceuticals has a market capitalization of $3.94 million and generates $23.99 million in revenue each year. The company earns $-8,280,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. Innovus Pharmaceuticals employs 27 workers across the globe.

What is Innovus Pharmaceuticals' official website?

The official website for Innovus Pharmaceuticals is www.innovuspharma.com.

How can I contact Innovus Pharmaceuticals?

Innovus Pharmaceuticals' mailing address is 8845 Rehco Road, San Diego CA, 92121. The company can be reached via phone at 858-964-5123 or via email at [email protected]

This page was last updated on 10/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.